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Although previous studies have demonstrated that the electro-
physiologic effects of many antiarrhythmic agents can be reversed 
by catecholamines, the susceptibility of amiodarone to such rever· 
sal is unknown. The objective of this study was to compare the 
relative degree of reversal of the electrophysiologic effects of 
quinidine and amiodarone by epinephrine infusions that result in 
plasma epinephrine levels similar to those achieved during various 
physiologic stresses. Twenty-nine patients who had inducible 
sustained monomorphic ventricular tachycardia and underwent 
electropharmacologic testing with quinidine and amiodarone were 
enrolled in the study. The variables measured before and during 
an epinephrine infusion (25 or 50 ng/kg per min) included the 
sinus cycle length, mean arterial pressure, QT interval and 
effective refractory period at drive train cycle lengths of 600 and 
400 ms. 
The effective refractory period measured at a drive train cycle 
length of 600 ms shortened less during amiodarone therapy (2 ± 
2%) than during quinidine therapy (6 ± 4%) or than in the 
baseline state (6 ± 4%; p < 0.01). Similar results were obtained 
during evaluation of the effective refractory period at a cycle 
length of 400 ms. Epinephrine infusion, at both 25 and 50 nglkg 
per min, completely reversed the effects of quinidine and partially 
Antiarrhythmic therapy guided by serial electrophysiologic 
studies has become a standard approach to the management 
of malignant ventricular arrhythmias (1). The suppression of 
inducible ventricular tachycardia by an antiarrhythmic agent 
is generally predictive of an excellent long-term response 
(2,3). However, several studies have reported recurrences of 
ventricular tachycardia in up to 32% of patients in whom it 
was suppressed by an antiarrhythmic agent during electro-
physiologic testing (4-6). Recent studies (7-13) have suggested 
that sympathetic activation may reverse or antagonize the 
effects of antiarrhythmic agents, and this phenomenon may be 
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reversed the effects of amiodarone on the effective refractory 
period. The effects of epinephrine on the sinus cycle length and QT 
interval were similar in the baseline state and in conjunction with 
quinidine and amiodarone. Twenty-four patients underwent pro-
grammed ventricular stimulation during amiodarone therapy 
alone and in conjunction with either a 25- or a 50-ng/kg per min 
infusion of epinephrine. None of the five patients whose ventric-
ular tachycardia was suppressed by amiodarone had sustained 
ventricular tachycardia induced during an epinephrine infusion. 
The ventricular tachycardia cycle length in patients with persis· 
tently inducible ventricular tachycardia also did not change after 
an epinephrine infusion. No patient receiving long-term amio· 
darone therapy has had a recurrence of ventricular tachycardia 
during a mean follow-up interval of 9 ± 4 months. 
The results of this study demonstrate that amiodarone is more 
resistant than quinidine to reversal of its electrophysiologic effects 
by epinephrine. This resistance may be due to the beta-adrenergic 
blocking properties of amiodarone and may explain, at least in 
part, the drug's unique long-term effectiveness in treating malig· 
nant ventricular arrhythmias. 
(JAm Coli Cardio/1992;19:347-52) 
one reason why electropharmacologic testing does not always 
accurately predict the long-term response to a drug. Although 
the electrophysiologic effects of most antiarrhythmic agents 
appear to be susceptible to reversal by catecholamines (7-12), 
it is possible that drugs such as amiodarone, which have 
beta-adrenergic blocking properties (14-16), are resistant to the 
antagonistic effects of sympathetic activation. However, the 
susceptibility of amiodarone to reversal of its effects by sym-
pathetic activation is unknown. 
The objective of this study was to compare the relative 
degree of reversal of the electrophysiologic effects of quini-
dine and amiodarone by epinephrine infusions that result in 
plasma catecholamine concentrations similar to those 
achieved during a variety of physiologic stresses. 
Methods 
Study patients. The subjects of this study were 29 pa-
tients with inducible sustained monomorphic ventricular 
tachycardia who underwent electropharmacologic testing 
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with both quinidine and amiodarone. The presenting ar-
rhythmia was sustained monomorphic ventricular tachycar-
dia in 16 patients, nonsustained ventricular tachycardia in 5, 
syncope in 5 and ventricular fibrillation in 3. Twenty-five 
patients were men and 4 were women. Their mean age was 
64 ± 9 years. Twenty-eight patients had coronary artery 
disease and had sustained a myocardial infarction at least 6 
months before their evaluation. One patient had a nonisch-
emic dilated cardiomyopathy. The mean left ventricular 
ejection fraction was 0.32 ± 0.11. 
Electrophysiologic testing. Electrophysiologic tests were 
performed with patients in the fasting state at least 5 half-
lives after discontinuation of all antiarrhythmic drugs includ-
ing beta-adrenergic blocking agents. The study protocol was 
approved by the Human Research Committee at the Univer-
sity of Michigan and informed consent was obtained from 
each patient. Quadripolar electrode catheters were inserted 
into a femoral vein and positioned at the high right atrium, 
across the tricuspid valve to record a His bundle electro-
gram, and at the apex of the right ventricle. A 5F cannula 
was inserted into a femoral artery for blood pressure moni-
toring. Leads V 1, I and Ill, the intracardiac electrograms and 
blood pressure were recorded at a paper speed of 25 mm/s 
with use of a Siemens-Elema Mingograf 7 recorder. Pro-
grammed stimulation was performed with a programmable 
stimulator (Bloom Associates) with stimuli that had a dura-
tion of 2 ms and a current intensity of twice diastolic 
threshold. 
Programmed ventricular stimulation was performed with 
up to 3 extrastimuli using 8-beat basic drive trains at cycle 
lengths of 600, 400 and 350 ms. If sustained monomorphic 
ventricular tachycardia was not induced at the cardiac apex, 
programmed stimulation with an identical protocol was 
repeated at the right ventricular septum or outflow tract. 
Sustained ventricular tachycardia was defined as ventricular 
tachycardia > 30 s in duration or requiring cardioversion for 
termination because of hemodynamic instability. 
All patients also underwent electrophysiologic testing 
after treatment with quinidine and amiodarone. Follow-up 
testing during quinidine therapy was performed :2::48 h after 
initiation of treatment with quinidine gluconate, 486 to 
648 mg three times/day. The follow-up electrophysiologic 
test was performed <2 h before the next scheduled dose. 
The mean plasma quinidine concentration at the time of 
follow-up electrophysiologic testing was 2.9 ± 0.8 mg/liter. 
Each patient still had inducible sustained monomorphic 
ventricular tachycardia during treatment with quinidine and 
was then treated with amiodarone. Follow-up electrophysi-
ologic testing during amiodarone therapy was performed 9 to 
10 days after initiation of treatment with amiodarone, 
1,800 mg/day in three divided doses. The mean plasma 
amiodarone concentration at the time of the electrophysio-
logic test was 2 ± 0.43 mg/liter. The programmed stimulation 
protocol during follow-up electrophysiologic testing was 
identical to the protocol used during the baseline electro-
physiologic test. 
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Epinephrine infusion. The electrophysiologic effects of 
epinephrine were determined in the baseline state and during 
treatment with quinidine and amiodarone. The variables 
measured before and during the epinephrine infusion in-
cluded the sinus cycle length, mean blood pressure, QT 
interval and ventricular effective refractory period at drive 
train cycle lengths of 600 and 400 ms. The QT interval was 
determined (to the nearest 10 ms) from an electrocardiogram 
(ECG) of the six limb leads recorded at a paper speed of 50 
or 100 mm/s during atrial pacing at a cycle length of 500 ms. 
The ventricular refractory period was determined by intro-
ducing an extrastimulus 290 ms after an 8-beat drive train 
that was followed by a 3-s pause. The coupling interval of the 
extrastimulus was progressively decreased in 10-ms steps 
until it failed to capture. The coupling interval was then 
increased in 2-ms steps until capture occurred. The effective 
refractory period was defined as the longest coupling interval 
at which the extrastimulus failed to capture. The effective 
refractory period was repeated to assure reproducibility to 
within 2 ms. After the baseline variables were obtained, 
epinephrine was infused at a dose of 25 ng/kg per min (17 
patients) or 50 ng/kg per min (12 patients). Previous studies 
have shown that a steady state epinephrine level is achieved 
after 10 min of a constant infusion (17,18). Therefore, after at 
least 14 min of epinephrine infusion, the electrophysiologic 
variables were remeasured. All patients except those who 
required cardioversion for termination of ventricular tachy-
cardia also had programmed ventricular stimulation repeated 
during treatment with amiodarone after an epinephrine infu-
sion. 
An infusion rate of 25 ng/kg per min has been demon-
strated to result in a mean plasma epinephrine concentration 
of 863 ± 226 pg/ml, which is similar to that achieved 
endogenously in response to submaximal exercise, cigarette 
smoking, public speaking and surgery (19-22). An infusion 
rate of 50 ng/kg per min has been demonstrated to result 
in a mean plasma epinephrine concentration of 1,374 ± 
477 pg/ml, which is similar to that achieved during maximal 
exercise, myocardial infarction, diabetic ketoacidosis and 
severe hypoglycemia (19-22). 
Statistical analysis. All data are expressed as mean values 
± 1 SD. The effects of epinephrine were assessed using a 
paired t test. The relative effects of epinephrine in the 
baseline state and during treatment with quinidine and 
amiodarone were compared by a repeated measures analysis 
of variance. Multiple comparisons were performed with 
Fisher's least significant difference procedure (23). A p value 
<0.05 was considered significant. 
Results 
Effects on arterial pressure. The mean baseline arterial 
pressure was 94 ± 18 mm Hg. Neither quinidine nor amio-
darone had any effect on this value, which also did not 
change during epinephrine infusions of 25 or 50 ng/kg per 
min. 
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Table 1. Effects of Epinephrine (E) on Sinus Cycle Length and QT Interval During Quinidine (Q) and Amiodarone (A) Therapy 
B B&E Q Q&E A A&E 
E, 25 ng/kg per min 
SCL (ms) 739 ± 130 667 ± 86 789 ± Ill 680 ± 100 933 ± 146 861 ± 136 
QT 500 (ms) 359 ± 30 341 ± 43 402 ± 50 386 ± 46 482 ± 43 461 ± 36 
E, 50 ng/kg per min 
SCL (ms) 732 ± 119 648 ± 89 766 ± 84 681 ± 100 902 ± 125 861 ± 159 
QT 500 (ms) 372 ± 21 353 ± 24 435 ± 45 415 ± 37 460 ± 56 429 ± 48 
p Values B vs. Q B vs. A B vs. B & E Q vs. Q & E A vs. A & E B vs. Q & E B vs. A & E 
E, 25 ng/kg per min 
SCL 0.07 < 0.01 < 0.01 < 0.01 0.02 0.04 0.01 
QT500 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 0.06 < 0.01 
E, 50 ng/kg per min 
SCL 0.2 < 0.01 < 0.01 < 0.01 0.16 0.01 <0.1 
QT 500 < 0.01 < 0.01 < 0.01 < 0.01 0.01 < 0.01 < 0.01 
Values other than p values are expressed as mean values ± SD. B =baseline; QT 500 = QT interval measured during atrial pacing at a cycle length of 500 ms; 
SCL = sinus cycle length. 
Effects on sinus cycle length and QT interval. Quinidine 
had no effect on the sinus cycle length, whereas amiodarone 
lengthened it by a mean of28 ± 26% (p < 0.01, Table 1). The 
25 ng!kg per min infusion of epinephrine shortened the sinus 
cycle length by a mean of 9 ± 8% during the baseline 
electrophysiologic test (p < 0.01) compared with a shorten-
ing of 14 ± 7% during treatment with quinidine (p < 0.01) 
and 7 ± 6% during treatment with amiodarone (p = 0.02). 
The effect of epinephrine on the sinus cycle length tended to 
be less in the presence of amiodarone than in the presence of 
quinidine (p = 0.07, Table 2). The effects of the 50-ng/kg per 
min infusion and the 25-ng/kg per min infusion of epineph-
rine were similar. The relative effects of the 50-ng/kg per min 
infusion of epinephrine were similar in the baseline state and 
in the presence of quinidine and amiodarone (p = 0.16, Table 
2). 
Both quinidine and amiodarone increased the QT inter-
val: quinidine by 11 ± 14% (p < 0.01) and amiodarone by 34 
± 12% (p < 0.01). The 25-ng/kg per min infusion of epineph-
rine shortened the QT interval by a mean of 5 ± 6% during 
the baseline electrophysiologic test (p < 0.01) versus a 
shortening of 4 ± 3% (p < 0.01) during treatment with 
quinidine and 4 ± 4% (p < 0.01) during treatment with 
amiodarone. The relative effects of epinephrine were similar 
Table 2. Relative Effects on Sinus Cycle Length and QT Interval 
B Q A p Value 
E, 25 ng/kg per min 
tSCL (ms) 73 ± 72 107 ± 60 73 ± 60 0.07 
tQT (ms) 19 ± 23 16 ± 14 22 ± 23 0.63 
E, 50 ng/kg per min 
! SCL (ms) 84 ± 76 85 ± 61 41 ± 91 0.16 
!QT (ms) 19 ± 11 20 ± 11 27 ± 35 0.33 
Values are expressed as mean values ± SD. ! QT = decrease in QT 
interval during atrial pacing at 500 ms; ! SCL = decrease in sinus cycle 
length; other abbreviations as in Table I. 
in the baseline state and in the presence of quinidine and 
amiodarone (p = 0.63 , Table 2). The effects of the 50-ng/kg 
per min infusion of epinephrine were similar to those of the 
25-ng/kg per min infusion. The relative effects of the 50-ng/kg 
per min infusion of epinephrine were also similar in the 
baseline state and in the presence of quinidine and amio-
darone (p = 0.33, Table 2). 
Effects on the ventricular effective refractory period. The 
ventricular effective refractory period measured at a drive 
train cycle length of 600 ms increased by 12 ± 6% during 
treatment with quinidine (p < 0.01) and by 12 ± 4% during 
treatment with amiodarone (p < 0.01, Table 3). Epinephrine, 
at an infusion rate of 25 ng!kg per min, shortened the 
effective refractory period by 6 ± 4% in the baseline state 
(p < 0.01), by 6 ± 4% during treatment with quinidine (p < 
0.01) and by 2 ± 2% during treatment with amiodarone (p < 
0.01). Epinephrine completely reversed the effects of quini-
dine on the effective refractory period and partially reversed 
those of amiodarone. The effective refractory period mea-
sured during quinidine therapy together with an epinephrine 
infusion was unchanged from the baseline state (p = 0.08). 
However, during amiodarone therapy the effective refrac-
tory period remained significantly longer during an epineph-
rine infusion than in the baseline state (p < 0.01). The effect 
of epinephrine in the presence of amiodarone was signifi-
cantly less than in the baseline state or in the presence of 
quinidine (p < 0.01, Table 4). Similar results were obtained 
during evaluation of the effective refractory period at a cycle 
length of 400 ms. 
The electrophysiologic effects of the 50-ng/kg per min 
epinephrine infusion in the baseline state and during quini-
dine and amiodarone therapy were similar to those of the 
25-ng/kg per min epinephrine infusion. Epinephrine short-
ened the effective refractory period and resulted in complete 
reversal of the effects of quinidine and partial reversal of the 
effects of amiodarone. Epinephrine, at an infusion rate of 
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Table 3. Effects on Ventricular Effective Refractory Period 
B B&E 
E, 25 ng/kg per min 
Q Q&E A 
JACC Vol. 19, No. 2 
February 1992:347-52 
A&E 
ERP 600 (ms) 258 ± 16 242 ± 14 287 ± 14 270 ± 14 293 ± 16 286 ± 18 
ERP 400 (ms) 240 ± 14 226 ± 11 265 ± 16 249 ± 14 273 ± 13 265 ± 19 
E, 50 ng/kg per min 
ERP 600 (ms) 263 ± 15 250 ± 15 300 ± 17 276 ± 16 308 ± 20 292 ± 25 
ERP 400 (ms) 244 ± 17 229 ± 18 281 ± 19 262 ± 17 284 ± 18 257 ± 21 
p Values B vs. Q B vs. A Q vs. Q & E A vs. A & E B vs. Q & E B vs. A & E 
E, 25 ng/kg per min 
ERP 600 < 0.01 < 0.01 < 0.01 < 0.01 0.08 < 0.01 
ERP 400 < 0.01 0.01 < 0.01 0.02 0.07 < 0.01 
E, 50 ng/kg per min 
ERP 600 < 0.01 < 0.01 < 0.01 < 0.01 0.05 < O.o! 
ERP 400 < 0.01 < 0.01 < 0.01 < 0.01 0.06 < 0.01 
Values other than p values are expressed as mean values ± SD. ERP 400 and ERP 600 = effective refractory period at a drive train of 400 
and 600 ms, respectively; other abbreviations as in Table I. 
50-ng/kg per min, had similar electrophysiologic effects in 
the baseline state and during treatment with quinidine and 
amiodarone (Table 4). 
Effects of epinephrine on induction of ventricular tachycar-
dia during amiodarone therapy. Consistent with the design 
of this study, each patient had inducible sustained monomor-
phic ventricular tachycardia in the baseline state and during 
treatment with quinidine. Follow-up programmed ventricu-
lar stimulation during amiodarone therapy demonstrated 
no inducible ventricular tachycardia in 5 patients, nonsus-
tained ventricular tachycardia in 1 patient (26 beats) and 
sustained monomorphic ventricular tachycardia in 23 pa-
tients. Twenty-four patients had programmed ventricular 
stimulation repeated during either a 25- (14 patients) or a 
50- (10 patients) ng/kg per min infusion of epinephrine. Four 
of these patients had no inducible ventricular tachycardia 
and one patient had nonsustained ventricular tachycardia 
induced during amiodarone therapy. None of these patients 
had inducible ventricular tachycardia during the epinephrine 
infusion (25 ng/kg per min in four patients and 50 ng/kg per 
min in one patient). Among the remaining 19 patients who 
had persistently inducible sustained monomorphic ventricu-
lar tachycardia during amiodarone therapy, ventricular 
Table 4. Relative Effects on Ventricular Effective 
Refractory Period 
p 
Baseline Quinidine Amiodarone Value 
E, 25 ng/kg per min 
t ERP 600 (ms) 16 ± 12 19 ± 10 6.4 ± 6.6 < 0.01 
! ERP 400 (ms) 14 ± 11 16.5 ± 10.5 6.9 ± 8.2 0.01 
E, 50 ng/kg per min 
t ERP 600 (ms) 16 ± 11 24 ± 13 16 ± 10 0.1 
t ERP 400 (ms) 14 ± 7 23 ± 13 17 ± 12 0.08 
Values are expressed as mean values± SD. t ERP 400 and t ERP 600 = 
decrease in effective refractory period at a drive train of 400 and 600 ms, 
respectively. 
tachycardia was no longer inducible in one patient after a 
25-ng/kg per min infusion of epinephrine. The ventricular 
tachycardia induced in the remaining 18 patients during 
either a 25- (9 patients) or a 50- (9 patients) ng/kg per min 
infusion of epinephrine had a similar configuration in 14 
patients and a different configuration in 4. The mean tachy-
cardia cycle length was not significantly different before (395 
± 74 ms) and during (378 ± 73 ms) the epinephrine infusion 
(p = 0.2). 
FoUow-up. Long-term therapy was guided by the re-
sponse to amiodarone during follow-up electrophysiologic 
testing. Five patients who had no inducible ventricular 
tachycardia or had inducible nonsustained ventricular tachy-
cardia were treated with amiodarone, 400 mg/day. Eight 
patients who had hemodynamically unstable ventricular 
tachycardia induced underwent placement of an implantab1e 
defibrillator. The remaining 16 patients had hemodynami-
cally stable ventricular tachycardia induced and were treated 
with amiodarone, 400 mg/day. During a mean follow-up 
period of 9 ± 4 months, no patient who received long-term 
treatment with amiodarone has had recurrent ventricular 
tachycardia or sudden cardiac death. 
Discussion 
The results of this study demonstrate that amiodarone is 
more resistant than quinidine to reversal of its electrophys-
iologic effects by epinephrine infused at rates that result in 
plasma epinephrine concentrations similar to those that 
occur endogenously during a variety of physiologic and 
pathologic stresses. Epinephrine resulted in less shortening 
of ventricular refractoriness during treatment with amio-
darone than during treatment with quinidine. Furthermore, 
in no patient were the antiarrhythmic effects of amiodarone 
reversed by epinephrine. 
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Differential reversal of the electrophysiologic effects of 
quinidine and amiodarone. Consistent with its known elec-
trophysiologic effects, quinidine prolonged the QT interval 
and increased ventricular refractoriness. Epinephrine at 
both low (25-ng/kg per min) and high (50-ng/kg per min) 
infusion rates partially or completely reversed the effects of 
quinidine on the QT interval and refractoriness. The ventric-
ular effective refractory periods during therapy with quini-
dine in conjunction with an epinephrine infusion were no 
different from those in the baseline drug-free state. Amio-
darone also prolonged the QT interval and refractoriness. 
However, low and high dose epinephrine infusions attenu-
ated but did not completely reverse the effects of amio-
darone. The effective refractory period during therapy with 
amiodarone, in contrast to that during quinidine therapy, 
remained significantly longer during an epinephrine infusion 
than that in the drug-free state. 
The differential antagonism of the electrophysiologic ef-
fects of quinidine and amiodarone indicates a relative resis-
tance of amiodarone to the effects of epinephrine. At an 
infusion rate of 25 ng/kg per min of epinephrine the degree of 
shortening of the effective refractory period was less during 
therapy with amiodarone than in the baseline drug-free state 
or during therapy with quinidine. This differential effect 
persisted but did not reach statistical significance at an 
epinephrine infusion rate of 50 ng/kg per min. Thus, the 
resistance of amiodarone to reversal by epinephrine appears 
to be dose dependent. 
Effects of epinephrine on the inducibility of ventricular 
tachycardia. The results of electropharmacologic testing 
during amiodarone therapy were not altered after an epi-
nephrine infusion. No patient whose sustained ventricular 
tachycardia was suppressed during amiodarone therapy had 
this arrhythmia induced during an epinephrine infusion, and 
no patient who had hemodynamically stable ventricular 
tachycardia induced during amiodarone therapy had hemo-
dynamically unstable ventricular tachycardia induced after 
infusion of epinephrine. None of the 22 patients treated long 
term with amiodarone have had recurrent ventricular tachy-
cardia during follow-up. These findings suggest that the 
antiarrhythmic actions of amiodarone, like its electrophysi-
ologic effects, are resistant to reversal by sympathetic acti-
vation. 
The resistance of amiodarone to reversal of its antiar-
rhythmic effects by epinephrine is in marked contrast to the 
findings of previous studies that have evaluated the effects of 
type I antiarrhythmic agents in conjunction with catechol-
amine infusions. Morady et al. (11) demonstrated that the 
results of electropharmacologic testing in patients with in-
ducible sustained momorphic ventricular tachycardia were 
significantly altered by epinephrine in 50% of patients 
treated with quinidine. Similarly, Jazayeri et al. (12) reported 
that isoproterenol reversed the therapeutic effects of type I 
antiarrhythmic agents in 59% of patients with ventricular 
arrhythmias. 
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Results of previous studies. No previous study has eval-
uated the electrophysiologic effects of catecholamines in 
conjunction with amiodarone therapy in patients with ven-
tricular tachycardia or has compared the relative effects of 
catecholamines on the actions of two antiarrhythmic agents. 
Brugada et al. (13) evaluated the effect of isoproterenol in 
patients with atrioventricular (A V) reciprocating tachycardia 
in the baseline state and during amiodarone therapy and 
reported similar electrophysiologic and antiarrhythmic ef-
fects of isoproterenol in the two groups. They concluded that 
amiodarone had minimal beta-blocking properties, and that 
amiodarone's antiarrhythmic actions were susceptible to 
reversal by catecholamines. This study differs from the 
present study in several important respects, which may 
explain the discrepant conclusions. First, in the study by 
Brugada et al. (13), different patients were studied in the 
drug-free state and during amiodarone therapy. Therefore, 
patients did not serve as their own controls. Second, their 
patients were treated with 200 mg/day of amiodarone 
whereas our study patients were tested after receiving a 
loading dose of 1,800 mg/day of amiodarone for 9 to 10 days. 
Amiodarone's beta-blocking properties may be dose depen-
dent. Third, Brugada et al. (13) evaluated the effect of 
isoproterenol titrated to achieve a 20% increase in heart rate. 
The physiologic relevance of this dose of isoproterenol is 
unknown. In our study, the effects of physiologic doses of 
epinephrine were evaluated. Finally, Brugada et al. (13) 
evaluated the effects of amiodarone therapy in patients with 
A V reciprocating tachycardia whereas the patients in our 
study had ventricular tachycardia. 
Several prior studies have reported that the electrophys-
iologic effects of type I antiarrhythmic agents can be antag-
onized by catecholamines in patients with supraventricular 
or ventricular arrhythmias. Morady et al. (11) demonstrated 
that physiologic levels of epinephrine completely or partially 
reversed the effects of quinidine. Other investigators have 
reported reversal of type I antiarrhythmic drug effects by 
catecholamines in patients with A V node reentrant tachy-
cardia (10) or A V reciprocating tachycardia (7 ,8). Antiar-
rhythmic drugs shown to be susceptible to reversal of their 
electrophysiologic actions by catecholamines include vera-
pamil (9), quinidine (7,11), encainide (10) and fiecainide (8). 
Thus, amiodarone's resistance to reversal of its antiarrhyth-
mic actions is unique among antiarrhythmic agents. 
Mechanism of differential antagonism. The precise mech-
anism of amiodarone's resistance to reversal of its electro-
physiologic and antiarrhythmic effects by epinephrine can-
not be determined from this study. However, this resistance 
may result from amiodarone's beta-blocking actions (14-16). 
Kadish et al. (15) recently demonstrated that amiodarone has 
beta-blocking effects in humans that are present within 2 
days of initiation of oral amiodarone therapy. This mecha-
nism is also consistent with a study by Manolis et al. (8), who 
demonstrated that propranolol can prevent reversal of the 
electrophysiologic effects of fiecainide by isoproterenol. 
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Clinical significance. Although previous studies (2-6) 
have demonstrated that the suppression of inducible ventric-
ular tachycardia during serial electrophysiologic testing is 
generally predictive of an excellent long-term response to an 
antiarrhythmic agent, ventricular tachycardia may recur in 
up to 32% of patients. This may be because electrophysio-
logic testing, which is generally performed in the rest state, 
does not evaluate the effects of antiarrhythmic agents after 
changes in autonomic tone. Previous studies (7-13) have 
demonstrated that sympathetic activation may reverse the 
electrophysiologic effects of type I antiarrhythmic agents. 
We have demonstrated that amiodarone is more resistant 
than is quinidine to reversal of its electrophysiologic effects 
by epinephrine. The relative resistance of amiodarone to 
sympathetic activation may explain, at least in part, amio-
darone's apparent unique long-term effectiveness in treating 
malignant ventricular arrhythmias (3 ,24,25). The results of 
this study, together with the results of previous studies 
(ll, 12), suggest that the long-term predictive accuracy of 
electropharmacologic therapy may be improved by routinely 
evaluating the efficacy of antiarrhythmic agents in the base-
line state and during a catecholamine infusion. Antiarrhyth-
mic agents whose antiarrhythmic actions are reversed during 
a catecholamine infusion may be more likely to be associated 
with a recurrence of tachycardia during follow-up, as com-
pared with antiarrhythmic agents whose effects are main-
tained during a catecholamine infusion. It is possible that the 
long-term efficacy of antiarrhythmic agents whose effects are 
demonstrated to be susceptible to reversal by increased 
sympathetic tone may be improved by concomitant therapy 
with beta-blockers. 
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